BR112017016428A2 - ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? - Google Patents
?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?Info
- Publication number
- BR112017016428A2 BR112017016428A2 BR112017016428A BR112017016428A BR112017016428A2 BR 112017016428 A2 BR112017016428 A2 BR 112017016428A2 BR 112017016428 A BR112017016428 A BR 112017016428A BR 112017016428 A BR112017016428 A BR 112017016428A BR 112017016428 A2 BR112017016428 A2 BR 112017016428A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- salt
- disorder
- acceptable compound
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
um composto de fórmula (i´) ou (i´´) ou um sal farmaceuticamente aceitável do mesmo. o composto é um inibidor de atividade de enzimas cinase de mamífero, incluindo atividade de tirosina quinase ror1 e pode ser usado no tratamento de distúrbios associados a tal atividade.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15153394.0 | 2015-02-02 | ||
EP15153394 | 2015-02-02 | ||
PCT/EP2016/052091 WO2016124553A1 (en) | 2015-02-02 | 2016-02-01 | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017016428A2 true BR112017016428A2 (pt) | 2018-04-10 |
BR112017016428B1 BR112017016428B1 (pt) | 2023-10-24 |
Family
ID=52449976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017016428-0A BR112017016428B1 (pt) | 2015-02-02 | 2016-02-01 | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável |
Country Status (14)
Country | Link |
---|---|
US (1) | US10550113B2 (pt) |
EP (1) | EP3253754B1 (pt) |
JP (1) | JP6629884B2 (pt) |
KR (1) | KR102493943B1 (pt) |
CN (1) | CN107567445B (pt) |
AU (1) | AU2016214492B2 (pt) |
BR (1) | BR112017016428B1 (pt) |
CA (1) | CA2973773C (pt) |
ES (1) | ES2875737T3 (pt) |
HK (1) | HK1247923A1 (pt) |
IL (1) | IL253380B (pt) |
MX (1) | MX2017009600A (pt) |
WO (1) | WO2016124553A1 (pt) |
ZA (1) | ZA201705933B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11660303B2 (en) | 2016-07-11 | 2023-05-30 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
ES2899113T3 (es) | 2016-07-11 | 2022-03-10 | Kancera Ab | Derivados de 2-fenilimidazo[4,5-b]piridin-7-amina útiles como inhibidores de la actividad tirosina quinasa ROR1 de mamíferos |
GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
JP7378267B2 (ja) | 2018-11-12 | 2023-11-13 | 東ソー株式会社 | コバルト錯体、その製造方法、及びコバルト含有薄膜の製造方法 |
CN112574176B (zh) * | 2019-09-27 | 2024-03-15 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7622479B2 (en) | 2001-11-26 | 2009-11-24 | Takeda Pharmaceutical Company Limited | Bicyclic derivative, its production and use |
SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
SE0202464D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Use of compounds |
JP2008521768A (ja) | 2004-12-23 | 2008-06-26 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用 |
EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
CA2596013C (en) | 2005-01-28 | 2012-06-05 | Daewoong Pharmaceutical Co., Ltd. | Benzoimidazole derivatives and pharmaceutical composition comprising the same |
US20110059941A1 (en) | 2005-05-24 | 2011-03-10 | Peter William Rodney Caulkett | 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
EP1963315B1 (en) | 2005-12-22 | 2014-10-08 | Cancer Research Technology Limited | Enzyme inhibitors |
US20090170847A1 (en) | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
WO2008121064A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705 |
EP2142542A4 (en) | 2007-03-30 | 2011-06-22 | Astrazeneca Ab | NEW IMIDAZO [4,5-B] PYRIDINE-7-CARBOXYLAMIDEAMIDE 704 |
WO2009001021A1 (en) | 2007-06-26 | 2008-12-31 | Chroma Therapeutics Ltd. | Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases |
JP2011513329A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | RAF阻害化合物として使用されるイミダゾ[4,5−b]ピリジン誘導体 |
US20120295915A1 (en) | 2009-11-24 | 2012-11-22 | Chaudhari Amita M | Azabenzimidazoles as fatty acid synthase inhibitors |
WO2011079902A2 (en) | 2009-12-18 | 2011-07-07 | Biolnvent International Ab | Biological materials and uses thereof |
WO2013116291A1 (en) * | 2012-01-30 | 2013-08-08 | Cephalon, Inc. | Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders |
-
2016
- 2016-02-01 AU AU2016214492A patent/AU2016214492B2/en active Active
- 2016-02-01 ES ES16702147T patent/ES2875737T3/es active Active
- 2016-02-01 EP EP16702147.6A patent/EP3253754B1/en active Active
- 2016-02-01 WO PCT/EP2016/052091 patent/WO2016124553A1/en active Application Filing
- 2016-02-01 KR KR1020177024661A patent/KR102493943B1/ko active IP Right Grant
- 2016-02-01 CA CA2973773A patent/CA2973773C/en active Active
- 2016-02-01 MX MX2017009600A patent/MX2017009600A/es active IP Right Grant
- 2016-02-01 US US15/545,523 patent/US10550113B2/en active Active
- 2016-02-01 BR BR112017016428-0A patent/BR112017016428B1/pt active IP Right Grant
- 2016-02-01 JP JP2017558782A patent/JP6629884B2/ja active Active
- 2016-02-01 CN CN201680008251.1A patent/CN107567445B/zh active Active
-
2017
- 2017-07-10 IL IL253380A patent/IL253380B/en unknown
- 2017-08-31 ZA ZA2017/05933A patent/ZA201705933B/en unknown
-
2018
- 2018-06-07 HK HK18107404.5A patent/HK1247923A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016214492B2 (en) | 2020-05-07 |
ES2875737T3 (es) | 2021-11-11 |
KR20170113629A (ko) | 2017-10-12 |
EP3253754B1 (en) | 2021-03-31 |
IL253380B (en) | 2021-07-29 |
CA2973773A1 (en) | 2016-08-11 |
WO2016124553A1 (en) | 2016-08-11 |
AU2016214492A1 (en) | 2017-08-24 |
BR112017016428B1 (pt) | 2023-10-24 |
JP2018507255A (ja) | 2018-03-15 |
EP3253754A1 (en) | 2017-12-13 |
IL253380A0 (en) | 2017-09-28 |
HK1247923A1 (zh) | 2018-10-05 |
ZA201705933B (en) | 2018-12-19 |
CN107567445B (zh) | 2021-06-29 |
KR102493943B1 (ko) | 2023-01-31 |
JP6629884B2 (ja) | 2020-01-15 |
CN107567445A (zh) | 2018-01-09 |
MX2017009600A (es) | 2017-11-22 |
US10550113B2 (en) | 2020-02-04 |
CA2973773C (en) | 2023-10-17 |
US20180002329A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
EP3569601A3 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
BR112017007460A2 (pt) | inibidores de di-hidropirrolopiridina de ror-gama | |
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
SA518391624B1 (ar) | Ror- منظمات جاما | |
PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
PH12016502353A1 (en) | Pharmaceutical composition | |
BR112018069515A2 (pt) | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica | |
TW201613577A (en) | Pharmaceutical combinations | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112018007947A2 (pt) | uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash | |
BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
BR112016029065A2 (pt) | ?composto, composição farmacêutica, e, uso de um composto? | |
PH12021550374A1 (en) | Small molecule menin inhibitors | |
BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
CO2022000270A2 (es) | Inhibidores de enzimas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2016, OBSERVADAS AS CONDICOES LEGAIS |